Table 2.

Characteristics of schizophrenia guidelines.

Guideline	Country	AP class specified (FGA/SGA)	Includes guidelines on dosing	Recommends treatment with specific AP	Includes recommendations for LAIs	Includes a treatment algorithm
APA, 202117	US	Yes	Yes	Yes	Yes	No
Florida Medicaid Program, 202018	US	Yes	Yes	Yes	Yes	Yes
BAP, 202033	UK	No	Yes	No	Yes	No
Oregon Health Authority, 201919	US	Yes	Yes	Yes	Yes	Yes
PPA, 201937,38	Poland	No	Yes	Yes	Yes	Yes
AACP, 201729	US	No	Yes	No	Yes	No
CPA, 201714	Canada	No	Yes	Yes	Yes	No
UNHCR, 201723	International	No	Yes	Yes	Yes	Yes
WFSBP, 201224, 201325, 201726	International	Yes	Yes	Yes	Yes	No
RANZCP, 201639	Australia and New Zealand	Yes	Yes	Yes	Yes	No
NICE, 201434	UK	Yes	Yes	No	Yes	No
AFPBN, 201340	France	Yes	No	No	Yes	No
CINP, 201322	International	No	Yes	Yes	Yes	No
SIGN, 201335	UK	Yes	Yes	Yes	Yes	No
Singapore Ministry of Health, 201136	Singapore	No	Yes	Yes	Yes	Yes
Schizophrenia PORT, 201030,31	US	Yes	Yes	Yes	Yes	No
Italian Guidelines, 200841	Italy	No	No	No	No	No
TMAP, 200828	US	Yes	Yes	Yes	Yes	Yes
NJDMHS, 200532	US	Yes	Yes	Yes	Yes	Yes

AACP American Association of Community Psychiatrists, AFPBN Association Française de Psychiatrie Biologique et Neuropsychopharmacologie, AP antipsychotic, APA American Psychiatric Association, BAP British Association of Psychopharmacology, CINP International College of Neuropsychopharmacology, CPA Canadian Psychiatric Association, LAI long-acting injectable, no not recommended, NA not applicable, NICE National Institute for Health and Care Excellence, NJDMHS New Jersey Division of Mental Health Services, NR not reported, PPA Polish Psychiatric Association, PORT Patient Outcomes Research Team, RANZCP Royal Australian/New Zealand College of Psychiatrists, SIGN Scottish Intercollegiate Guidelines Network, TMAP Texas Medication Algorithm Project, UNHCR United Nations High Commissioner for Refugees, WFSBP World Federation of Societies of Biological Psychiatry, yes recommended.